Nizatidine

FDA Approved: * July 5, 2002
Pharm Company: * MYLAN
Category: Ulcer

Nizatidine is a histamine H2 receptor antagonist that inhibits stomach acid production, and is commonly used in the treatment of peptic ulcer disease and gastroesophageal reflux disease.[1] It was patented in 1980 and approved for medical use in 1988.[2][3] It was developed by Eli Lilly. Brand names include Tazac and Axid. Contents 1 Medical use 2 Adverse effects 3 History and development 4 See also 5 References 6 External links Medical u... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.
3 Discussions

Dosage List

Nizatidine E150
Nizatidine 150 mg Oral Capsule
NDC: 0185-0150
Labeler:
Eon Labs, Inc.
Nizatidine E300
Nizatidine 300 mg Oral Capsule
NDC: 0185-0300
Labeler:
Eon Labs, Inc.
Nizatidine MYLAN;5150
Nizatidine 150 mg Oral Capsule
NDC: 0378-5150
Labeler:
Mylan Pharmaceuticals Inc.
Nizatidine MYLAN;5300
Nizatidine 300 mg Oral Capsule
NDC: 0378-5300
Labeler:
Mylan Pharmaceuticals Inc.
Nizatidine WPI;3137
Nizatidine 150 mg Oral Capsule
NDC: 0591-3137
Labeler:
Watson Laboratories, Inc.
Nizatidine G46;150
Nizatidine 150 mg Oral Capsule
NDC: 68462-425
Labeler:
Glenmark Generics Inc., USA
Nizatidine E150
Nizatidine 150 mg Oral Capsule
NDC: 16590-741
Labeler:
Nizatidine
Nizatidine E150
Nizatidine 150 mg Oral Capsule
NDC: 21695-375
Labeler:
Rebel Distributors Corp
Nizatidine WPI;3137
Nizatidine 150 mg Oral Capsule
NDC: 42254-093
Labeler:
Rebel Distributors Corp
Nizatidine WPI;3137
Nizatidine 150 mg Oral Capsule
NDC: 52959-824
Labeler:
H.j. Harkins Company, Inc.
More Results

Related Brands

Drugs with the same active ingredients